Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Astegolimab, an anti-ST2 monoclonal antibody designed to block signaling of IL-33 under development by Roche's (OTCQX:RHHBY) Genentech unit, failed to meet its primary endpoint in a phase 3 trial for ...

Regeneron Pharmaceuticals, Inc.'s stock continues to remain in the accumulation phase even after the setbacks associated primarily with itepekimab and Eylea. At the same time, Dupixent will remain ...

NEW YORK CITY, NY / ACCESS Newswire / July 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ( ...

Merck has agreed to a $10-billion buyout of Verona Pharma and its first-in-class, potential COPD blockbuster Ohtuvayre.

Itepekimab, an investigational monoclonal antibody for chronic obstructive pulmonary disease (COPD), demonstrated mixed results in a pair of phase 3 studies evaluating the treatment in former ...

Itepekimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6547] ...

In AERIFY-2, however, itepekimab failed to hit this same threshold, showing only a 2% reduction in exacerbations at 52 weeks. “Sentiment has undoubtedly been poor for REGN shares of late following the ...

RBC Capital also reaffirmed its Sector Perform rating with a $662 price target, following challenges with the itepekimab program. RBC’s investor survey indicated a desire for strategic changes, such ...

On May 30, 2025, Sanofi issued a press release announced mixed data from a Phase 3 program for itepekimab, an antibody therapy targeting the lung disorder chronic obstructive pulmonary disease ...